Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Excluded participants also had lower blood levels of 25-hydroxyvitamin D3 and lower urinary levels of creatinine and osmolality.
Source: Selection of participants. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
The baseline survey was conducted between 2003 and 2006 and included 6733 participants aged between 35 and 75 years.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Association between urinary heavy metal/trace element concentrations and kidney function: a prospective study
Study design awaiting verification · Clinical Kidney Journal · 2025
Original publication title
Association between urinary heavy metal/trace element concentrations and kidney function: a prospective study
© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Chronic kidney disease (CKD) is an important public health problem. Although cross-sectional studies have identified many heavy metals/trace elements associated with reduced kidney function, prospective studies are needed to determine the pathogenic role of these elements in the development and progression of CKD.
Source: BackgroundAbstract: What methods does the paper describe?
To explore the association between baseline urinary heavy metal/trace element concentrations and long-term impaired kidney function (IKF)/CKD, as well as the incidence of rapid decline in kidney function in a population-based exploratory prospective study, with mean age 51.9 years at baseline whose urinary trace elements concentrations have been determined by inductively coupled plasma mass spectrometry. IKF was defined by a reduced estimated glomerular filtration rate (eGFR) between 60 and 90 mL/min/1.73 m2, and CKD was defined as an eGFR <60 mL/min/1.73 m2.
Rapid eGFR decline was defined as a decrease ≥3 mL/min/1.73 m2/year.
Source: MethodsAbstract: Results
Over a mean follow-up of 12.5 years, 123 participants (2.6%) experienced rapid decline in kidney function, and 1455 (31.7%) developed IKF or CKD. After adjusting for covariates including baseline eGFR, we found that urinary vanadium [hazard ratio (HR) = 1.07, 1.03 to 1.12], cobalt (HR = 1.69, 1.21 to 2.37), nickel (HR = 1.19, 1.08 to 1.3), copper (HR = 1.03, 1.01 to 1.06), selenium (HR = 1.33, 1.02 to 1.73), molybdenum (HR = 1.48, 1.2 to 1.82) and iodine (HR = 1.1, 1.02 to 1.2) were associated with an increased risk of new incident IKF or CKD cases during the follow-up.
Also, urinary copper [odds ratio (OR) = 1.12, 1.04 to 1.21], silver (OR = 1.83, 1 to 3.35), molybdenum (OR = 1.02, 1.01 to 1.04) and cadmium (OR = 1.05, 1.01 to 1.09) were associated with an increased risk of rapid eGFR decline.
Source: ResultsAbstract: Conclusion
In the general population, several urinary heavy metals/trace elements are associated with a rapid decline in kidney function or new cases of IKF/CKD.
Source: ConclusionAuthors’ abstract
ABSTRACT
Background
Chronic kidney disease (CKD) is an important public health problem. Although cross-sectional studies have identified many heavy metals/trace elements associated with reduced kidney function, prospective studies are needed to determine the pathogenic role of these elements in the development and progression of CKD.
Methods
To explore the association between baseline urinary heavy metal/trace element concentrations and long-term impaired kidney function (IKF)/CKD, as well as the incidence of rapid decline in kidney function in a population-based exploratory prospective study, with mean age 51.9 years at baseline whose urinary trace elements concentrations have been determined by inductively coupled plasma mass spectrometry. IKF was defined by a reduced estimated glomerular filtration rate (eGFR) between 60 and 90 mL/min/1.73 m2, and CKD was defined as an eGFR <60 mL/min/1.73 m2.
Rapid eGFR decline was defined as a decrease ≥3 mL/min/1.73 m2/year.
Results
Over a mean follow-up of 12.5 years, 123 participants (2.6%) experienced rapid decline in kidney function, and 1455 (31.7%) developed IKF or CKD. After adjusting for covariates including baseline eGFR, we found that urinary vanadium [hazard ratio (HR) = 1.07, 1.03 to 1.12], cobalt (HR = 1.69, 1.21 to 2.37), nickel (HR = 1.19, 1.08 to 1.3), copper (HR = 1.03, 1.01 to 1.06), selenium (HR = 1.33, 1.02 to 1.73), molybdenum (HR = 1.48, 1.2 to 1.82) and iodine (HR = 1.1, 1.02 to 1.2) were associated with an increased risk of new incident IKF or CKD cases during the follow-up.
Also, urinary copper [odds ratio (OR) = 1.12, 1.04 to 1.21], silver (OR = 1.83, 1 to 3.35), molybdenum (OR = 1.02, 1.01 to 1.04) and cadmium (OR = 1.05, 1.01 to 1.09) were associated with an increased risk of rapid eGFR decline.
Conclusion
In the general population, several urinary heavy metals/trace elements are associated with a rapid decline in kidney function or new cases of IKF/CKD.
Publication and source details
Original title: Association between urinary heavy metal/trace element concentrations and kidney function: a prospective study
Sisi Xie; Maïwenn Perrais; Déla Golshayan; Gregoire Wuerzner; Julien Vaucher; Aurélien Thomas; Pedro Marques-Vidal
Clinical Kidney Journal · 2025
Correspondence to: Pedro Marques-Vidal; E-mail: Pedro-Manuel.Marques-Vidal@chuv.ch© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.2025https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Faculty of Biology and Medicine of Lausanne Swiss National Science Foundation10.13039/501100001711 33CSCO-12266133CS30-13946833CS30-14840133CS30_177 53531003A-1824203 247 730_204 523320 030_220 190 GlaxoSmithKline10.13039/100004330 Fondation pour la recherche sur le diabète Swiss Personalized Health Network 2018DRI01Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T08:18:56.659761+00:00
DOI: 10.1093/ckj/sfae378 · PMC11822291